We present functional and binding data relevant to the reported roles for prothrombin and /32-glycoprotein I (p2GPI) in the expression of lupus anticoagulant activity. In a purified system containing human prothrombin, Xa, Va, and a ratelimiting concentration of phosphatidylserine (PS)/phosphatidylcholine (PC) vesicles, the preliminary incubation of vesicles with protein A separated IgG preparations from 10 lupus anticoagulant plasmas, calcium, and prothrombin enhanced the inhibitory effect of all IgG preparations upon thrombin generation. Experiments in a purified factor X activation system provided supporting data that a similar preliminary incubation with prothrombin enhanced the inhibitory effect of many of the IgG preparations upon factor X activation.
in plasma from patients with systemic lupus erythematosus, that inhibited prothrombinase-catalyzed activation of prothrombin by presumably reacting with the phospholipid component of prothrombinase. Today, the name is widely used for a common laboratory phenomenon demonstrable in plasma of patients with diverse immune disorders in addition to systemic lupus erythematosus and resulting from autoantibodies that can impair the function of anionic phospholipid in a variety of phospholipid-dependent coagulation tests. ' An association between acquired circulating anticoagulants in systemic "collagen disease" and plasma antibodies reacting with the cardiolipin antigen used in serologic tests for syphilis was described almost 40 years ago.3 As additional patients with lupus and the combination of an anticoagulant and false positive serology were identified, it was suggested that both phenomena could represent manifestations of closely related antibodies reacting with phospholipid. 4 After the introduction of techniques for quantitating Passage of five citrated lupus anticoagulant plasmas through a prothrombin affinity column in the absence of added calcium and phospholipid removed most of the activity prolonging the d R W of normal plasma, and IgG in the pass-through plasma no longer bound t o PS in the presence of prothrombin and calcium ions. IgG in prothrombin column eluates had strikingly enhanced specific lupus anticoagulant activity and also specific PS binding activity in the presence of Prothrombin and calcium ions. Thus, lupus anticoagulant plasmas were shown t o contain IgG binding t o prothrombin, in the absence of calcium ions and phospholipid, which could also, in the presence of calcium ions and prothrombin, bind t o PS and express lupus anticoagulant activity. serum anticardiolipin antibody titers in the 1 980s5.' and their subsequent widespread clinical application, it became evident that most but not all patients with a lupus anticoagulant also have an elevated titer of anticardiolipin antibodies and, conversely, that most but not all patients with an elevated titer of anticardiolipin antibodies also have a lupus anticoagulant.'" This indirect evidence for the existence of related but different phospholipid binding autoantibodies was buttressed by direct evidence that anticardiolipin antibodies could be separated from antibodies with lupus anticoagulant activity in the plasma of several patients possessing both types of antibodies.'","
Studies of the binding to anionic phospholipid of a lupus anticoagulant IgM paraprotein'? and of several lupus anticoagulant IgG preparations" were initially viewed as direct evidence, supporting the earlier inferential functional evidence, that most, if not all, lupus anticoagulants are antibodies with immunologic specificity towards anionic phospholipids. However, evidence had been presented more than 30 years for the hypothesis that prothrombin is required as a cofactor for the expression of lupus anticoagulant activity, It was also recognized many years ago that patients with the lupus anticoagulant could have an accompanying second coagulation abnormality-acute, severe hypoprothrombinemia. The hypoprothrombinemia did not stem from the presence of circulating neutralizing antibodies to prothrombin4 and was later shown to be associated with a concordant depletion of plasma prothrombin antigen.l5~'' A mechanism for the hypoprothrombinemia became apparent with the demonstration of antibodies that bound prothrombin without neutralizing its coagulant activity in the plasma of two patients with the acquired hypoprothrombinemia-lupus anticoagulant syndrome."
In a key report published in 1984,*' it was reported that antiprothrombin antibodies were present not only in patients with the acquired hypoprothrombinemia-lupus anticoagulant syndrome but were also demonstrable by crossed immunoelectrophoresis in the plasma of most patients with the lupus anticoagulant. This finding was confirmed in a second study2' in which it was also shown that adsorption of lupus anticoagulant plasmas with insolubilized prothrombin not only removed prothrombidprothrombin antibody complexes but also diminished the ability of the plasma to express lupus anticoagulant activity prolonging the dilute Russell's viper venom time (dRVVT). Because lupus anticoagulant IgG was thought at that time to bind directly to anionic phospholipids, a hypothesis was proposed of polyreactivity of lupus anticoagulant IgG extending beyond anionic phospholipids to include epitopes on prothrombin. " In 1990, two groups of in~estigators"~~~ reported that affinity-purified anticardiolipin (aCL) antibodies could bind to anionic phospholipids only in the presence of a plasma component, which was identified as p2 glycoprotein I (P2GPI). Thus, earlier studies in which antibodies with anticardiolipin and lupus anticoagulant activities were removed from lupus anticoagulant plasmas by adsorption onto cardiolipin lipo~omes'~~" can no longer be accepted as evidence that lupus anticoagulant antibodies have immunologic specificity towards anionic phospholipids. Rather, they may be viewed as evidence that the adsorbed antibodies recognized an epitope formed after the binding of P2GPI to anionic phospholipid. Recent report^^"^' that P2GPI is required for some lupus anticoagulant plasmas or lupus anticoagulant IgG preparations to express anticoagulant activity support this conclusion.
However, in a recent study in which 16 lupus anticoagulant plasmas containing aCL antibodies were adsorbed with liposomes containing cardiolipin,28 it was found that the aCL antibodies were sedimented with the liposomes in all 16 patients, whereas lupus anticoagulant activity remained in the supernatant in 11 plasmas. The IgG remaining in the supernatant of two plasmas was studied further and shown to inhibit prothrombinase-catalyzed generation of thrombin when human prothrombin was the substrate but not when bovine prothrombin was the substrate. Moreover, because this IgG could be adsorbed onto liposomes in the presence of prothrombin and calcium ions, these investigators concluded that this type of lupus anticoagulant autoantibody is not directed to phospholipids alone, but recognizes an epitope that becomes exposed after the calcium ion-mediated binding of human prothrombin to phospholipids. The anticoagulant activity sedimenting with the liposomes in 5 of the 16 lupus anticoagulant plasmas was later reported27 to stem from the ability of a subgroup of aCL antibodies, referred to as aCLtype A, to enhance binding of P2GPI to negatively charged phospholipid with resultant impaired prothrombinase-catalyzed generation of thrombin from either human or bovine prothrombin.
Thus, the literature contains evidence that phospholipiddependent coagulation reactions may be impeded by two types of antibodies in lupus anticoagulant plasmas, one requiring the presence of prothrombin and the other requiring the presence of p2GPI. This prompted us to perform the experiments reported here in which functional data are provided from both purified and plasma systems on the ability of prothrombin and P2GPI to affect the expression of anticoagulant activity of IgG separated from lupus anticoagulant plasmas by both protein A affinity chromatography and prothrombin affinity chromatography. Data are also provided on the ability of IgG preparations to bind to prothrombin and P2GPI on Western blots and to immobilized phosphatidylserine (PS) in an enzyme-linked immunosorbent assay (ELISA).
MATERIALS AND METHODS
Plasma specimens. Platelet-poor plasma from 10 patients and from normal subjects was prepared at UCSD Medical Center from venous blood collected in llloth volume of buffered citrate anticoagulant and centrifuged either one or two times at 4,000s for IO minutes. Platelet-poor plasma in buffered citrate anticoagulant from three patients was received from other institutions.
Standard coagulation tests. The activated partial thromboplastin time (APTT) was performed with Automated APTT reagent (Organon Teknica, Durham, NC), the prothrombin time (PT) with thromboplastin C (American Dade, Aguada, Puerto Rico), and the specific prothrombin (factor 11) activity with a substrate containing aged human serum and aluminum hydroxide-adsorbed bovine plasma (Dade, Baxter Healthcare Corp, Miami, K).
Phospholipid vesicles. Acidic phospholipid vesicles containing 40% PS and 60% phosphatidylcholine (PC) were prepared with octylglucopyranoside as the detergent" as a stock 1 mg/mL suspension.
Pur$ed human clotting factors. Prothrombin and factors IX and X were purified as described earlier." Factor IX was activated just before use by incubating 10 pglmL of factor IX with 0.5 pg/mL of factor XIa in 5 m o U L Ca2+ for 1 hour at 37°C. Factor X was activated with Russell's viper venom as described earlier.3' Factor V was purified as described by Kane and Majerus3' and activated with thrombin as previously d e~c r i b e d .~~ Lyophilized human factor VI11 (Monoclate-P Armour Pharmaceutical CO, Kankakee, IL) was reconstituted in the manufacturer's diluent in a concentration of approximately 85 U/mL and stored in small aliquots at -80°C. Factor VI11 was activated with purified human thrombin (gift of Dr J.W. Fenton, New York State Department of Health, Albany, NY) at a ratio of 125:l (Urn) for 1 minute at 37°C and used immediately.
PZGPI. P2GPI was purified from human plasma as previously described by Polz et al. 34 The purified material migrated as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under both nonreduced and reduced conditions. Preparations were tested by the Rheumatology Laboratory of the UCSD Medical Center for their ability to function as a cofactor in an anticardiolipin binding assay and were found to enhance by fivefold to 18-fold the ability of a final 5,000-fold dilution of a known anticardiolipin antibody positive serum to bind to a cardiolipin-coated well blocked with gelatin in 1% bovine serum albumin (BSA). Aminotermina1 sequencing of the purified preparation used in virtually all of the present experiments showed a single amino acid sequence at each cycle as follows: Gly-Arg-Thr-X-Pro-Lys-Pro-Asp-Asp-Leu.
This corresponds to the published aminoterminal amino acid sequence of P2GPI.3s
Separation of IgG from patient plasmas and control plasmas by protein A chromatography. Plasma samples were clotted with purified human thrombin and IgG was separated from the resultant sera by affinity chromatography on a protein A column (Pierce, Rockford, IL). IgG samples appeared homogenous on both reduced and nonreduced SDS-PAGE analysis and were devoid of phospholipid activity as evaluated by their inability to support prothrombin activation in reaction mixtures in which no other source of phospholipid was present. (In our hands, IgG separated with a protein A column obtained from another manufacturer possessed a small amount of pro-
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coagulant phospholipid activity supporting prothrombin activation and also contained other minor contaminants.)
Separation of IgC from patient plasmas by prothrombin affinity chromatography. Purified prothrombin was coupled to Affi-Gel-IS beads at a concentration of 8 mg/mL of resin as described earlier." BSA was coupled to beads at a concentration of 14 mg/mL to prepare a control column. Two to 3 mL of lupus anticoagulant plasma was passed through a S-mL prothrombin affinity column at a flow rate of approximately 6 mL per hour at 4°C. The pass-through plasma was collected and stored at -80°C. The column was washed with about 100 mL of Tris-buffered saline (SO mmol/L Tris-HCI, 0.15 mol/L sodium chloride, pH 7.5). When the absorption at 280 nm approached zero, the column was washed with 50 mL of Tris buffer containing I molL sodium chloride. Bound proteins were then eluted with 0.1 mol&. glycine, pH 2.4, and fractions were collected into tubes containing I/lOth volume of I molL Tris to adjust the pH to 7.5. Fractions containing protein as determined by absorption at 280 nm were pooled and dialyzed in Tris-buffered saline overnight at 4°C before testing.
P reparation of rabbit antihuman prothrombin and rabbit antihuman PZGPI IgC. Polyclonal antibodies were raised in rabbits to purified prothrombin and to purified P2GPI by injecting S0 p g of purified protein in Freund's complete adjuvant at multiple intradermal sites and at two intramuscular sites. Four weeks after the first immunization, 50 pg of the protein in incomplete adjuvant was injected at multiple subcutaneous sites and at two intramuscular sites. The rabbits were bled periodically starting 1 week after the boost. Sera were heat-inactivated at 56°C for 30 minutes and the IgG fraction was separated by precipitation at 40% ammonium sulfate saturation followed by diethylaminoethyl (DEAE)-Affi-Gel blue chromatography (Bio-Rad Laboratories, Richmond, CA).
Depletion of P2GPIfrom normal plasma. The rabbit antihuman PZGPI IgG described above, which was found to recognize only P2GPI on immunoblotting of human plasma, was coupled to AffiGel-IO (Bio-Rad) according to the manufacturer's technical bulletin at a concentration of 12 mg IgG/mL of beads. Three milliliters of normal plasma was passed slowly through a S -m L anti-PZGPI IgG column and the pass through was collected in 0.5-mL fractions. The least diluted plasma fractions were pooled and stored at -80°C. A control non-PZGPI-depleted plasma was prepared by passing 3 mL of plasma through a 5-mL control nonimmune IgG column. Both plasmas were diluted about twofold by this procedure. Mean p2GP1 antigen levels of three preparations, measured by the ELISA described below, were as follows: for the starting plasma, 220 pg/ mL; after passing through the anti-PZGPI column, S p g h L (2 to 8 pg/mL); after passing through the control column, 131 pg/mL.
Modijied dRVVT. One hundred microliters of test plasma were incubated for 2 minutes at 37°C. Then, 100 pL DVV test reagent (American Diagnostica Inc, Greenwich, CT), which had been warmed to 37T, was added to initiate clotting. factor X . In a preliminary experiment, a linear increase in the rate of prothrombin activation was observed with increasing concentrations of PUPS vesicles between 0.004 pg/ mL and 0 . 1 pg/mL in a prothrombin activation system containing the following fixed final concentrations of other reactants: Xa. 0 . I pg/mL; Va, 3 pg/mL; prothrombin, I O 0 pg/mL; and CaCl,, S mmol/ L (data not shown). Therefore, a final concentration of 0.06 pg/mL of PSlPC vesicles was selected as a rate-limiting concentration that should be sensitive to an effect of lupus anticoagulant 1gC upon phospholipid function in our purified prothrombin and factor X activation systems.
Prothrombin activation system. In the prothrombin activation system, 20 pL of patient IgG or control 1gG (1.3 to 2 mg/mL) was incubated in a microtiter well for 30 minutes with 20 pL of PS/PC (0.06 pg/mL); 20 pL of prothrombin (100 yg/mL) or P2GPI ( l00 pg/mL) or control buffer; and 20 pL of calcium chloride (8 mmol/ L). Prothrombin activation was then initiated by the addition of 20 p L of a mixture of factor Xa (0.1 pg/mL) and factor Va (3.0 @g/ mL) and, if not present in the preliminary mixture, 20 pL of prothrombin (1 00 pg/mL). After I O minutes, 10 pL of EDTA ( I 6 mmol/ L) was added to terminate thrombin generation. A 20-pL subsample was removed and diluted fivefold by addition to a well containing 80 pL of TBSIBSA. Thrombin was measured by adding SO /AL of l .25 mg/mL of the amidolytic substrate Chtomozym TH (Boehringer Mannheim, Indianapolis, IN) and measuring the initial rate of color development as mOD/min at 405 nm wave length in a continuously recording microplate reader (Molecular Devices, Menlo Park, CA). All concentrations listed above and in subsequent reaction mixtures are final concentrations. Under our conditions of assay, S U/mL of human thrombin gave a value of 80 mOD/min. Modifications of the above in specific experiments are described in Results and in the figure legends.
Factor X activation system. In the factor X activation system, 30 pL of patient IgG or control IgG (4 to S mg/mL) was incubated in a microtiter well for 30 minutes with 5 p L of PUPS vesicles (0.06 pg/mL): S pL of prothrombin (2 p g h L ) or PZGPI ( I O 0 p g / mL) or control buffer; and S y L of calcium chloride (S mmolk). Then, S pL of factor IXa (0.2 yg/mL); S pL of S U/mL thrombinactivated factor VIII; and 5 pL of factor X (20 pg/mL) were added. After S minutes, 5 pL of EDTA (16 mmolk) was added to terminate generation of factor Xa, followed by 50 pL of the chromogenic substrate chromozym X (Boehringer Mannbeim). Factor Xa activity was measured by monitoring the initial rate of color development as described above.
ELISA for prothrombin. Rabbit antihuman prothrombin IgG (100 pL of 25 pg/mL in 0.1 m o l k sodium carbonate buffer, pH 9.6) was coated on a 96-well microtiter plate for 2 hours at room temperature followed by blocking with 3% BSA in TBS for 2 hours. Then, 100 pL of test sample was added to duplicate wells and incubated for 1 hour at room temperature. After removing unbound samples, the plate was washed four times with TBS containing 0.05% Tween-20. Then. 100 p L of reporter antibody, biotinylated rabbit antihuman prothrombin IgG (50 pg/mL), was added to each well. After 1 hour at room temperature, unbound reporter antibody was removed and the plate was washed four times with TBS containing Tween, Then, 100 pL of biotinylated peroxidase-avidin complex (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) was added to each well and allowed to stand for 30 minutes at room temperature. The wells were then washed three times with TBS containing Tween and one time with TBS and 1 0 0 p L of peroxidase substrate (Peroxidase substrate kit ABTS; Bio-Rad) was added to For personal use only. on October 30, 2017. by guest www.bloodjournal.org From each well. Color was developed for 20 minutes and measured as absorbance at 405 nm in a microplate reader. Known concentrations of prothrombin between 12.5 ng/mL and 2.5 pg/mL were included on each plate to construct a standard curve.
ELJSA for PZGPI. The assay for P2GPI was as described above for prothrombin except that rabbit antihuman P2GPI IgG was the antibody used and its concentration as the reporter antibody was 25 pg/mL. Known concentrations of purified P2GPI from 2.5 ng/mL to 100 ng/mL were included on each plate to construct a standard ELISA for the binding of IgG to PS in the presence of PZGPI, prothrombin, or control buger. Microplate wells were coated under a continuous nitrogen stream with 40 pL of PS (Sigma, St Louis, MO) in ethanol (50 pg/mL) or with ethanol alone. The wells were blocked with Tris-buffered saline containing 0.3% gelatin and 1% BSA for 90 minutes at room temperature. Fifty microliters of test sample, either diluted plasma or IgG, was added to each well along with 50 pL of prothrombin (10 pg/mL) or P2GPI (IO pg/mL) or control buffer. When the IgG was total IgG separated by protein A chromatography, the final IgG concentration in the well was 50 pgl mL. After 90 minutes of incubation at room temperature, unbound test sample was removed and the wells were washed four times with TBS. Then, 100 pL of 1,000-fold diluted horseradish peroxidaseconjugated goat F(ab'), fragments of antihuman IgG (Tago, Burlingame, CA) was added to each well. After 1 hour, the unbound secondary antibody was removed, the wells were washed four times with TBS, and 100 pL of peroxidase substrate was added to each well. The color developing over 30 to 60 minutes was measured as OD at 405 nm and the absorbance obtained with ethanol-coated wells was subtracted from the absorbance obtained with PS-coated wells to obtain specific binding of the test sample to PS.
Binding was measured in the absence and in the presence of calcium ions. For binding in the absence of calcium ions, the diluent for all reagents and the control buffer was the blocking agent, ie, Tris-buffered saline containing 0.3% gelatin and 1% BSA. For binding in the presence of calcium ions, the diluent and control buffer also contained CaC12 (5 mmol/L).
Determination of the spec@ PS binding activity of rest materials after prothrombin aJinity chromatography. A starting lupus anticoagulant plasma was diluted serially from 200-fold to 1,600-fold and the dilutions were assayed for PS binding activity in the presence of prothrombin (10 pg/mL) diluted in calcium-containing buffer to construct a standard curve. Test samples of pass-through plasma from the prothrombin affinity column were assayed under the same conditions at a 200-fold dilution. Test samples of eluates from the prothrombin affinity column were assayed under the same conditions at a 40-fold to 400-fold dilution and one or more mOD readings that fell within the standard curve were used to calculate binding as a percentage of the binding activity of the starting plasma. The percentage of binding activity was divided by protein concentration, determined as described above, to obtain a value for specific activity of binding.
Binding on Western blots of IgG separated by protein A chromatography to prothrombin and P2GPI. Purified human prothrombin or purified P2GPI (50 pg per gel) were subjected to SDS-PAGE according to the method of L a e~n i l l i~~ in 8% to 12% polyacrylamide gels. The proteins were transferred for immunoblotting to a polyvinyldifluoride (PVDF) membrane according to the method of Towbin et al. 37 Immunoblotting was performed with IgG separated from lupus anticoagulant plasmas by protein A chromatography and, as controls, with rabbit antihuman P2GPI and rabbit antihuman prothrombin IgG. Details are given in the figure legends.
curve.
RESULTS
Patients were identified as having a lupus anticoagulant on the basis of the following criteria: (1) a prolonged APTT, dRVVT, or both that failed to correct 00 a 1 : 1 mixture with normal plasma; (2) 50% or less of normal activity of at least two of those factors that are measured in one-stage partial thromboplastin time assays, namely, factors XII, XI, IX, and VI11 (but excluding factor IX if the patient was receiving warfarin); (3) evidence that the measured activity of one or more of the above mentioned clotting factors increased with increasing dilution of the patient's plasma in the assay, and (4) no evidence of another cause for the above clotting abnormalities.
Pertinent clinical and laboratory findings of 10 patients whose plasmas were used for our functional studies are summarized in Table 1 . Patients Cr, Ga, and Lo, who were studied because of abnormal bleeding, had a markedly prolonged PT and were found to have an associated severe hypoprothrombinemia. Patients Te, Ka, and Ad had moderately prolonged PTs but were receiving warfarin when studied. Patients Te, Hu, Sh, and Ka had a history of thrombosis not attributable to other causes. Patient Sa had experienced pulmonary emboli but at laparotomy for a pelvic mass was found to have a fibroid tumor that was compressing an iliac vein. As shown in Table 1 Figure 1 illustrates the effect of an initial 30-minute incubation of lupus anticoagulant IgG from patient Te with PS/PC vesicles and calcium ions-in the presence and in the absence of prothrombin-upon the progress curves of thrombin generation in our prothrombin activation system. One notes that activation rates were linear and that the inhibitory effect of the lupus anticoagulant IgG was discernable in the IO-minute subsample. Therefore, in further studies we felt it adequate to evaluate the effect of experimental variables upon prothrombin activation by measuring the thrombin concentration in a single IO-minute sample taken from the reaction mixture.
In an additional experiment in which the components of an initial incubation were varied, it was found that all three components-prothrombin, phospholipid, and calcium ions-had to be present with the lupus anticoagulant IgG for an initial incubation to enhance maximally the ability of the IgG to inhibit thrombin generation. The average values from two experiments performed with patient Te IgG ( 1 mg/ mL) for the amidolytic activity of thrombin in the IO-minute sample were as follows: for the complete initial incubation mixture, 6 mOD/min; for the incubation mixture lacking prothrombin, 39 mOD/min; for the incubation mixture lacking phospholipid. 38 mOD/min; and for the incubation mixture lacking calcium ions, 33 mOD/min. When control IgG was substituted for patient IgG. the values for thrombin generation ranged from 58 to 69 mOD/min independent of the composition of the initial incubation mixture. Nevertheless, in other experiments in which phospholipid vesicles were excluded not only from the initial incubation mixture but from the complete reaction mixture, the resultant diminished thrombin generation because of the absence of phospholipid observed in reaction mixtures containing control IgG was still further reduced in reaction mixtures containing patient Te IgG or other lupus anticoagulant IgG preparations tested (data not shown).
The inhibitory effect upon thrombin generation of the lupus anticoagulant IgG preparations from all IO patients of Table 1 is summarized in Fig 2. Three points should be noted. The first is that all preparations inhibited thrombin generation to some degree without the need for an initial incubation of the IgG with exogenous prothrombin, PSPC vesicles, and calcium ions. The second is that three of the lupus anticoagulant IgG preparations strikingly inhibited thrombin generation in the absence of such a preliminary incubation mixture. These were IgG preparations from the patients Cr. Ga, and Lo of Table 1 , who had presented with evidence of abnormal bleeding and an associated severe hypoprothrombinemia. The third point is that, with all of the lupus anticoagulant IgG preparations, a preliminary incubation of the IgG with prothrombin, phospholipid, and calcium ions enhanced the inhibition of thrombin generation.
In the above experiments, prothrombin was present in the preliminary incubation mixture at a 100 pg/mL concentration, ie, at its substrate concentration. Further experiments were performed with lupus anticoagulant IgG preparations from 6 patients to determine how low the prothrombin concentration could be reduced in the preliminary incubation mixture and still obtain a maximum effect on the ability of the IgG to inhibit phospholipid function in prothrombin activation. For the three lupus anticoagulant IgG preparations that markedly inhibited prothrombin activation without a preliminary incubation (see Fig 2) . the IgG concentration had to be reduced to between 0.25 and 0.0625 mg/mL to N Lo Cr Ga Ka Te Ta Hu Sh Sa Ad Lupus Anticoagulant IgG Prothrombin Conc., vg/ml perform this experiment. At these IgG concentrations, a prothrombin concentration of only 0.25 to 1.0 pg/mL in the preliminary incubation mixture sufficed to yield maximum inhibition (data not shown). In contrast, for the lupus anticoagulant IgG preparations from patients Te and Ta, which were used at a concentration of 1 mg/mL for this experiment, and for the IgG preparation from patient Hu, which was used at a concentration of 2 mg/mL, a prothrombin concentration of 1 to 10 pg/mL in the preliminary incubation mixture was required for a maximum inhibitory effect. The data obtained with patient Te IgG are shown in Fig 3. Further experiments were performed with patient Te IgG in which 0.6 pg/mL of prothrombin fragment 1 (equimolar to 2 pg/mL prothrombin) was substituted for 2 pg/mL prothrombin in the preliminary incubation mixture. A preliminary incubation with prothrombin fragment 1 failed to enhance the ability of patient Te IgG to inhibit thrombin generation (data not shown).
The effect of a preliminary incubation of lupus anticnagulant IgG with 02GPI. phospholipid, and calcium ions on prothrombin activation. We next performed experiments in which the prothrombin in the preliminary incubation mixture was replaced with 100 pg/mL of /32GPI. As shown in Fig 4 , a preliminary incubation with P2GP1, PSlPC vesicles, and calcium ions failed to enhance the inhibitory effect of any lupus anticoagulant IgG preparation on thrombin generation. In further experiments in which both 100 pg/mL of prothrombin and 100 pg/mL of P2GPI were added to preliminary incubation mixtures, the enhanced inhibitory effect of the preliminary incubation was similar to that observed when the preliminary incubation mixture contained only prothrombin (data not shown).
The effect of lupus anticoagulant IgG preparations on the activation of factor X. Because prothrombin must be 2883 present as substrate, the prothrombin activation system could not be used to evaluate whether prothrombin is an obligatory cofactor for lupus anticoagulant IgG to inhibit the procoagulant activity of PS/PC vesicles. Therefore, additional experiments were performed on the effect of a preliminary incubation of IgG preparations with prothrombin, PS/PC vesicles, and calcium ions on the ability of lupus anticoagulant IgG preparations to inhibit the IXa/Vllla/phospholipid-catalyzed activation of factor X. A 2 pg/mL final concentration of prothrombin was selected for the preliminary incubation mixture because, as cited earlier, this concentration of prothrombin in preliminary incubation mixtures had yielded a substantial inhibitory effect with six lupus anticoagulant IgG preparations, and we wanted to eliminate any possible effects of a higher concentration of prothrombin on the assay system. The final concentration of IgG was increased to 4 to S mg/mL to enhance the possibility of detecting inhibition of phospholipid function when the preliminary incubation mixture contained control buffer in place of added prothrombin. Progress curves of activation obtained with lupus anticoagulant IgG from 3 patients showed that the IgG from patients Cr and Ga (Fig SA and B) , but not from patient Te (Fig X ) , inhibited factor X activation in the absence of added prothrombin in the preliminary incubation mixture. Nevertheless, when prothrombin was added to the initial incubation mixture, the ability of all three lupus anticoagulant IgG preparations to inhibit the activation of factor X was increased. It was also clear from these progress curves of activation that the effect of lupus anticoagulant IgG on factor X activation could be evaluated in further experiments by measuring factor Xa in a S-minute subsample from the activation mixture.
The data obtained from S-minute subsamples in further experiments with all IO lupus anticoagulant IgG preparations from the patients of Table 1 are summarized in Fig 6. Five of the IO lupus anticoagulant IgG preparations (patients Lo, Cr. Ga, Sh, and Sa) significantly diminished the rate of factor X activation ( P < .02) in the absence of a preliminary incubation of the IgG with prothrombin, PS/PC vesicles, and calcium ions. Nevertheless, a preliminary incubation with 2 pg/mL prothrombin, PSPC vesicles, and calcium ions enhanced the ability of four of the lupus anticoagulant IgG preparations to inhibit factor X activation ( P values between .OS and ,001 for patients Lo, Cr, Ga, and Te). In contrast, a preliminary incubation failed to enhance the activity of the other six lupus anticoagulant IgG preparations, two of which had significant inhibitory activity in the absence of a preliminary incubation (patients Sh and Sa).
As a second part of these experiments, 100 pg/mL of P2GPI was substituted for 2 p.g/mL of prothrombin in the preliminary incubation mixtures. With seven of the lupus anticoagulant IgG preparations, the preliminary incubation N Lo Cr Ga Ka Te T a Hu Sh Sa 4d
Lupus Anticoagulant IgG with P2GP1, PSPC vesicles, and calcium ions was without measurable effect. In 3 patients, preliminary incubation of the lupus anticoagulant IgG with 100 pg/mL of P2GPI appeared to increase its inhibitory effect but not to the extent observed on incubation of the lupus anticoagulant IgG with 2 pg/mL of prothrombin. Moreover, the increase was marginal for patient Ga IgG ( P = .OS) and not significant for patient Te IgG ( P = .07) or patient Ta IgG ( P = .17).
Because the lupus anticoagulant IgG preparations from 5 patients inhibited phospholipid-dependent activation of factor X in the absence of added prothrombin, it became important to verify that our reaction mixtures were indeed free of prothrombin. When the factor X preparation was incubated with a snake venom prothrombin activator, Ecarin (Sigma), it was found that 1 mg of the factor X preparation contained approximately 8 pg of prothrombin. Thus, the 20 pg/mL of factor X added as substrate had supplied 0.16 pg/ mL of prothrombin to each final reaction mixture. The lupus anticoagulant IgG preparations were also checked for prothrombin antigen in our prothrombin ELISA. As shown in Table 2 , eight of the nine lupus anticoagulant IgG preparations tested had prothrombin antigen levels significantly higher (from about 40 to about 800 nglmg) than the levels measured in three control IgG preparations (2 to 4 ng/mg). Thus, control initial incubation mixtures not containing an added 2 pg/mL of prothrombin nevertheless contained from about 0. I6 pg/mL to about 4 pg/mL of prothrombin supplied by the 4 to S mg/mL concentration of these lupus anticoagulant IgG preparations in the mixtures. P2GPI antigen levels were also measured by ELISA in the IgG preparations and were not higher than the levels measured in control IgG preparations.
The ahi1ir.v of lupus anticoagulant IgG to prolong the dRVVT of plasma depleted of 02GPI. As mentioned earlier, there are report^'^"' that P2GPI must be present to obtain a prolonged dRVVT with plasma from some lupus anticoagulant patients or for isolated IgG from such patients to prolong the dRVVT of normal plasma. Therefore, we performed additional experiments in which lupus anticoagulant IgG from 9 of the patients (IgG from Cr was no longer available) was added to normal plasma that had been passed through a control nonimmune IgG column (plasma P2GPI antigen level, 107 to 177 pg/mL) and to normal plasma that had been passed through an anti-P2GPJ IgG column (plasma P2GPI antigen level, 2 to 8 pg/mL). Removing the P2GPI from normal plasma did not diminish the ability of the lupus anticoagulant IgG preparations to prolong the dRVVT ( Table  3) . This was true for both IgG preparations in which P2GPJ enhanced binding of IgG to immobilized PS and for IgG preparations in which P2GPJ did not enhance such binding (see below).
The inhibitoly effects of rabbit antihuman P2GPI &G in phospholipid-dependent coagulation systems.
In contrast to the behavior of the lupus anticoagulant IgG preparations, Twenty-five microliters of nonimmune IgG or anti-02GPI IgG (6 to 8 rng/mL) was added to normal or P2GPI-depleted plasma and clotting times were measured as described in the footnote to Table 3 . The lgGs were prepared from antisera from two rabbits immunized with purified 02GPI. * The longer dRVVT obtained with normal IgG than obtained in the experiments of Table 3 reflects greater dilution of plasma in this experiment during the chromatography.
the addition of rabbit antihuman 02GPI IgG was found to prolong the dRVVT of normal plasma that had been passed through a control nonimmune IgG column but not to prolong the dRVVT of normal plasma that had been passed through an anti-02GPI IgG column (Table 4) . Adding 100 pg/mL of our P2GPI preparation to the P2GPI-depleted plasma restored the ability of the antihuman 02GPI JgG to prolong the dRVVT, eg, from a 49-second clotting time of the P2GPI-depleted plasma to a 69-second clotting time after the addition of the P2GPJ.
The behavior of the rabbit antihuman 02GPI IgG was also evaluated in the purified systems for the activation of prothrombin (Fig 7A) and for the activation of factor X ( Fig  7B) . As the progress curves of activation illustrate, the rabbit anti-02GPJ IgG inhibited activation in both of these purified assay systems in the presence but not in the absence of P2GPJ. Prothrombin failed to support rabbit anti-P2GPI For personal use only. on October 30, 2017. by guest www.bloodjournal.org From IgG-induced inhibition of activation in either purified system.
Binding of lupus anticoagulant IgG to immobilized PS. The ability of lupus anticoagulant IgG from 10 patients, in a final concentration of 50 pg/mL, to bind to immobilized PS in the absence of calcium ions was evaluated in the presence of buffer, purified prothrombin (10 pg/mL), or purified P2GPI (10 pg/mL; Table 5 1 l ) , possibly because of the high background signal repeatedly observed with this preparation. Moreover, although patient Tl's plasma had strong lupus anticoagulant activity in clinical coagulation assays, the IgG preparation prolonged the dRVVT of normal plasma only moderately, and it is believed that this patient had primarily an IgM lupus anticoagulant.
In contrast to their ability to bind to purified prothrombin, none of the 10 IgG preparations bound on Western blots to purified PZGPI (Fig 9) . Only the positive control probe, rabbit antihuman PZGPI IgG (lane 13), gave a signal with the /32GPI.
The effect of prothrombin afjinity chromatography of lupus anticoagulant plasmas on anticoagulant activity. Five lupus anticoagulant plasmas were subjected to prothrombin affinity chromatography. One of these plasmas (from patient Hu) was also passed through a control column of BSA coupled to Affi-Gel-15. The starting plasmas, the pass-through plasmas, and the eluates from the prothrombin column were assayed for lupus anticoagulant activity by measuring their ability to prolong the dRVVT and to inhibit the generation of Xa in our purified factor X activation system. SDS-PAGE analysis of the eluates confirmed that they primarily contained protein with the mobility of IgG. Western blots of the eluates with rabbit antihuman prothrombin IgG and with rabbit antihuman b2GPI IgG were negative. Prothrombin PS in the presence of control buffer or 82GPI.
PS in the presence of control buffer or prothrombin.
plasma that had substantially less lupus anticoagulant activity.
normal IgG and lupus anticoagulant IgG in the presence of buffer.
* P < .005 as calculated for differences of individual IgG binding to t P < .01 as calculated for differences of individual IgG binding to t These data were from IgG separated from a later sample of Ga § P < .05 as calculated for the differences between PS binding of 1 p < .05 as calculated for differences of individual IgG binding to hours, the lanes were washed five times with TBS containing 5 mmol/L EDTA and then probed with labeled protein A (100.000 cpm/mL) for 90 minutes at room temperature. After this, the membrane was washed five times with TBS and exposed overnight t o x-ray film at -8O' C. lgG preparations were as follows: lanes 1 t o 5, lupus anticoagulant IgG from patients Cr. Ga, Hu, Lo, and Ne; lane 6, normal IgG; lanes 7 through 9, lupus anticoagulant IgG from patients Ro, Sh, and Ta; lanes l 0 and ll, lgG from patient TI; lane 12, lupus anticoagulant IgG from patient Te. Lane 13 was probed with rabbit antihuman prothrombin 1gG and shows a major prothrombin band and a second band with a mobiliw-corresponding t o prethrombin 1.
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13 concentrations of eluates as measured in our ELISA for prothrombin were less than 50 ng of prothrombin per 30 pL of eluate.
The addition to normal plasma of test samples from patient Hu yielded the following clotting times in the modified dRVVT: for buffer as an inert test sample, 40 seconds; for Hu starting plasma diluted twofold to compensate for dilution because of column chromatography, 65 seconds; for Hu plasma after passage through the control column, 66 seconds; for Hu plasma after passage through the prothrombin affinity column, 44 seconds; and for Hu eluate (240 pg/mL protein) from the prothrombin column, 53 seconds. Table 7 is a summary of the dRVVT data converted into values for specific lupus anticoagulant activity (see Materials and Methods) from all five plasmas subjected to prothrombin affinity chromatography. A single passage through the prothrombin column, in the absence of calcium ions and anionic phospholipid, reduced the specific lupus anticoagulant activity of the pass-through plasma to about 15% to 30% of the specific lupus anticoagulant of the starting plasma. The specific lupus anticoagulant activity of prothrombin eluate IgG was over 100-fold higher than the specific lupus anticoagulant activity of the starting plasmas. Table 8 is a summary of the data obtained when four of five prothrombin column eluates were tested for their ability to impair PS/PC-supported IXaNIIIa activation of factor X. (Prothrombin eluate IgG from patient Hu was not used in this experiment to conserve the eluate IgG for use in the experiment of Table 9 ). After their initial incubation with prothrombin (2 pg/mL), P S K vesicles, and calcium ions, all four prothrombin column eluate IgGs inhibited the ability of PSPC vesicles to support the activation of factor X.
The effect of prothrombin affinity Chromatography of lupus anticoagulant plasmas on the binding of IgG to immohilized PS in the presence of prothrombin and CaCI,. The starting plasmas, the prothrombin column pass-through plasmas, and the eluates from the prothrombin column were also tested for their ability to bind to PS in the presence of prothrombin (10 pg/mL) and calcium ions. An example of the values obtained for one patient (Hu) were as follows: for a 200-fold dilution of starting plasma, 0.34 OD; for a 200-fold dilution of the plasma after passage through the control column, 0.32 OD; for the eluate from the control BSA column, no measurable OD; for a 200-fold dilution of plasma after passage through the prothrombin column, 0.05 OD; and for a 160-fold dilution of eluate from the prothrombin column, 0.39 OD.
Data were qualitatively similar for all the plasmas but, because of nonlinearity of standard curves with two starting plasmas in the presence of prothrombin in the assay, data could be expressed as specific PS binding activity for only three plasmas (Table 9 ). Prothrombin affinity chromatography removed more than 75% of the ability of these starting plasmas to bind to PS in the presence of prothrombin and calcium ions. Prothrombin column eluate IgGs bound to PS-in the presence of prothrombin ( I O pg/mL) and calcium ions-with a 130-to 400-fold increase in specific activity over that present in the starting plasmas. In contrast, prothrombin column eluate lgGs failed to bind to PS in the presence of calcium ions alone.
In further experiments in which 10 pg/mL of prothrombin was replaced with IO pg/mL of P2GPI, converse data were obtained. The pass-through plasmas from the prothrombin affinity column had virtually the same ability to bind to PS 
DISCUSSION
The present studies extend earlier evidence from ~t h e r s '~. '~ that prothrombin can function as a cofactor for the expression of lupus anticoagulant activity and provide evidence that this stems from antibodies in lupus anticoagulant plasma with specificity towards prothrombin. In initial studies with IgG separated from lupus anticoagulant plasmas by protein A chromatography, we used purified systems containing a rate- limiting concentration of PSPC vesicles to determine the effect of a preliminary incubation of the IgG with PSPC vesicles, prothrombin, and calcium ions on the subsequent ability of the PS/PC vesicles to support the generation of thrombin and of factor Xa. In the prothrombin activation system, the lupus anticoagulant IgG separated from the plasma of each of the 10 patients of Table 1 inhibited thrombin generation to some degree without the need for the preliminary incubation. The extent of inhibition was striking with the IgG from 3 patients (patients Lo, Cr, and Ga of Table l) , who had presented with bleeding and the acquired hypoprothrombinemia-lupus anticoagulant syndr~me?'~.~' Nevertheless, with all preparations an initial incubation of lupus anticoagulant IgG with prothrombin, PS/PC vesicles and calcium ions increased the ability of the IgG to inhibit thrombin generation (Fig 2) . Thus, one may reasonably assume that, in the experiments in which prothrombin was absent from a preliminary incubation, a reaction between lupus anticoagulant IgG, prothrombin, PSPC vesicles, and calcium ions after addition of prothrombin as substrate contributed to the ability of lupus anticoagulant I g G to impair the function of PSPC vesicles in supporting thrombin generation.
In the experiments of Fig 2, prothrombin was present in the preliminary incubation mixture in a 100 pg/mL concentration. However, for five of six IgG preparations tested with lower concentrations of prothrombin in the preliminary incubation mixture, a final concentration of from 0.25 to 1 pg/mL of prothrombin sufficed to enhance the ability of the
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IgG to impair the subsequent function of the PSPC vesicles in the generation of thrombin. These concentrations are less than 1% of normal plasma prothrombin concentration.
A purified prothrombin activation system could not be used to test whether prothrombin was an absolute requirement for our lupus anticoagulant IgG preparations to inhibit the coagulant activity of anionic phospholipid. Therefore, we tested whether a preliminary incubation of lupus anticoagulant IgG with P S R vesicles, prothrombin in a 2 pg/ mL concentration, and calcium ions was required for lupus anticoagulant IgG to inhibit IXaNIIIalphospholipid-catalyzed activation of factor X. A final concentration of added prothrombin of only 2 pg/mL was used to minimize competition for limiting PSPC binding sites between prothrombin and the 20 pg/mL of factor X present in the final reaction mixture and also to minimize any possible amidolytic effect of thrombin on the chromogenic substrate of the assay.
As seen from the progress curves of activation of Fig  5A and B and from the data summarized in Fig 6, lupus anticoagulant IgG in 5 of the 10 preparations (from patients Lo, Cr, Ga, Sh, and Sa) appeared to inhibit P S R function in factor X activation without the need for a preliminary incubation of the IgG with prothrombin, P S R vesicles, and calcium ions. Three of these IgG preparations (from patients Lo, Cr, and Ga) had exhibited the highest inhibitory activity in the prothrombin activation experiments (Fig 2) . It is noteworthy that a preliminary incubation of these three IgG preparations, as well as of a fourth IgG preparation (from patient Te), with 2 p g / d of exogenously added prothrombin, PS/ PC vesicles, and calcium ions enhanced the ability of the lupus anticoagulant IgG preparations to inhibit PSPC function in factor X activation (Fig 5A, B, and C and Fig 6) .
These data failed to provide conclusive evidence that prothrombin was an obligatory cofactor for the lupus anticoagulant IgG preparations to inhibit anionic phospholipid function. This is believed to have stemmed from the fact that Eluates from the prothrombin affinity column were concentrated fivefold and the activation of factor X was performed after initial incubation of IgG with prothrombin (2 pg/mL), PS/PC vesicles (0.06 pg/ mL), and calcium ions (5 mmol/L), followed by the addition of IXa The PS binding activity present in 1 mL of starting plasma was assigned a value of 1,000 mu.
incubation mixtures containing control buffer instead of 2 pg/mL of added prothrombin turned out, nevertheless, to contain from 0.2 to 4 pg/mL of prothrombin as a contaminant of the lupus anticoagulant preparations. These trace concentrations of prothrombin were presumably copurified with lupus anticoagulant IgG on protein A chromatography because of the binding of prothrombin to the protein A column as prothrombidIgG complexes. Such complexes have been shown by crossed immunoelectrophoresis"**' to be present in the plasma of the majority of patients with a lupus anticoagulant.
Thus, the data of Fig 6 may be accepted as evidence that the inhibition observed with seven of the 10 lupus anticoagulant IgG preparations after incubation with either control buffer or added exogenous prothrombin represented inhibition that followed incubation of the IgG with PSPC vesicles and calcium ions in the presence of prothrombin. One should also note that the three IgG preparations (from patients Ta, Hu, and Ad) that failed to inhibit the activation of factor X after preliminary incubation in mixtures containing either control buffer or 2 pg/mL of added prothrombin were preparations that had inhibited activation of prothrombin only modestly in the absence of their preliminary incubation with a 100 p g / d concentration of prothrombin (Fig 2) . Therefore, we suspect that an inhibitory effect of these lupus anticoagulant IgG preparations on factor X activation might have been measurable if a higher concentration of added prothrombin had been used in the preliminary incubation mixture.
In contrast to the data for prothrombin, preliminary incubation of the 10 lupus anticoagulant IgG preparations with 100 pg/mL of P2GP1, PSPC vesicles, and calcium ions failed to enhance the ability of IgG preparations to inhibit the function of P S R vesicles in the activation of either prothrombin (Fig 4) or of factor X (Fig 6) . Because it has been reported that P2GPI was needed for the antibodies in some lupus anticoagulant plasmas and IgG preparations to prolong the dRVVT,25-27 we performed additional experiments to determine whether P2GPI was required for our lupus anticoagulant IgG preparations to prolong the dRVVT of normal plasma. Preparations available from 9 of the 10 patients of Table 1 were found to prolong equally the dRVVT of normal plasma and of plasma depleted of 02GPI (Table 3 ). The P2GPI-depleted plasma had only 2 to 8 pg/ mL residual P2GP1, which is far less than the 50 pg/mL P2GPI concentration reported to be required for 02GPI to support the expression of lupus anticoagulant activity in plasma.25 Thus, our data are consistent in failing to provide evidence that P2GPI was needed for the lupus anticoagulant IgG preparations we studied to impair coagulant phospholipid function in either plasma or purified systems.
Because plasma from most lupus anticoagulant patients will contain aCL antib~dies,~.~ ie, antibodies thought now to recognize epitopes formed after the binding of p2GPI to anionic phospholipid, we thought it unlikely that our negative functional data with p2GPI resulted from the absence of such antibodies from all of our lupus anticoagulant IgG preparations. Evidence was obtained that a number of our lupus anticoagulant IgG preparations contained IgG that bound to immobilized PS in increased amount in the presence of P2GPI (Tables 5 and 6 ).
There are reports that antibodies raised to human P2GPI can impair the coagulant function of anionic phospholi~id.'~.~' In contrast to our lupus anticoagulant IgG preparations, our rabbit antihuman P2GPI IgG prolonged the dRVVT of normal plasma but failed to prolong the dRVVT of normal plasma depleted of P2GPI (Table 4) . When 100 pg/mL of our P2GPI preparation was added back to the P2GPI-depleted plasma, the ability of the rabbit antihuman P2GPI IgG to prolong the dRVVT of the plasma was restored. Moreover, when the rabbit antihuman P2GPI IgG was incubated with PSPC vesicles and calcium ions for 30 minutes in the presence but not in the absence of 100 pg/ mL of our P2GPI preparation, the IgG impaired the function of PSPC vesicles in both our purified prothrombin and factor X activation systems (Fig 7) . These results assured us that our P2GPI preparation was functionally active and that an interaction between P2GPI and lupus anticoagulant IgG that diminished the coagulant function of PSPC vesicles would have been measurable in our assay systems.
It is now clear that two types of aCL antibodies can be adsorbed from lupus anticoagulant plasmas onto liposomes containing anionic ph~spholipid.~~~" One type, referred to as type A, was found to possess lupus anticoagulant activity and was present in 5 of 16 plasmas studied. The second type, referred to as type B, was devoid of lupus anticoagulant activity and was present in the remaining 1 l Apparently, the antibodies in our lupus anticoagulant preparations that bound to immobilized PS in the presence of P2GPI were all type B-aCL antibodies. Patient heterogeneity accounts best for the difference between our results and those of investigators who have described lupus anticoagulant activity that was dependent on the presence of P2GPI.
In contrast to the data for P2GP1, calcium ions had to be present for the increased binding of lupus anticoagulant IgG to PS in the presence of prothrombin (Tables 5 and 6 ), ie, for the binding which is presumably involved in the mechanism whereby prothrombin functions as a cofactor for the expression of lupus anticoagulant activity. In this regard, we recognize that statistically significant increased binding in the presence of prothrombin and calcium ions was obtained with only five of the preparations (Table 6 ), whereas evidence of binding to prothrombin on Western blots was obtained for 9 of 10 lupus anticoagulant IgG preparations and evidence for a cofactor function for prothrombin was obtained with all 10 lupus anticoagulant IgG preparations of Table L. The reason for this difference in results is unknown but possibly related to the washes involved in the assay for binding to immobilized PS and the low concentration (50 pg/mL) of IgG used in the assay.
Two mechanisms could result in the binding of lupus anticoagulant IgG to PS in the presence of prothrombin and calcium ions. In one, which has been accepted as the mechanism by other investigator^,^^.^"^ the lupus anticoagulant IgG would recognize an epitope that becomes exposed after the calcium ion mediated binding of prothrombin to PS. In the other, the lupus anticoagulant IgG would recognize an epitope or epitopes on prothrombin and come down onto PS as a "passenger" after the calcium-ion mediated binding of prothrombin to PS.
Our data provide two types of evidence that IgG from lupus anticoagulant plasmas can bind to prothrombin in the absence of phospholipid and calcium ions. First, it was shown (Fig 8) that IgG separated by protein A affinity chromatography from 9 of 10 lupus anticoagulant plasmas (including plasma from 7 of the patients of Table 1 ) bound to prothrombin on Western blots in the presence of EDTA. This was in sharp contrast to their inability to bind on Western blots to P2GPI (Fig 9) .
Second, in experiments confirming an earlier observation from this laboratory,2' substantial quantitative data were obtained that the majority of lupus anticoagulant activity could be removed from five citrated plasma samples by their adsorption with insolubilized prothrombin in the absence of phospholipid ( Table 7) . The pass-though plasmas were almost devoid of IgG, with measurably enhanced binding to PS in the presence of prothrombin and calcium ions ( Table  9 ). In contrast and as expected, the pass-through plasmas still contained IgG with enhanced binding to PS in the presence of P2GPI.
IgG eluted from the prothrombin column had markedly increased specific lupus anticoagulant activity in a dRVVT assay ( Table 7 ) and, after its incubation with 2 pg/mL prothrombin, PSPC vesicles, and calcium ions, impaired the activation of factor X (Table 8) . Prothrombin column eluate IgG also bound with markedly enhanced specific activity to immobilized PS when both prothrombin and calcium ions were present ( Table 9) , but was unable to bind to PS in the presence of calcium ions alone.
Earlier prothrombin adsorption data from this labordtory"-obtained at a time when there appeared to be evidence that lupus anticoagulants were antibodies with immunologic specificity towards anionic phospho1ipids""was thought to support a hypothesis that lupus anticoagulant IgG possessed polyreactivity, allowing its independent binding to epitopes on anionic phospholipid and to epitopes on prothrombin. This hypothesis is no longer tenable. Although one group of investigators believes that at least one population of antibodies with lupus anticoagulant activity is phospholipid specific:" the data presented here add to the earlier data anticoagulant plasmas, with possible rare exceptions (eg, patient Ta, see Table 6 ), do not contain IgG directed primarily against anionic phospholipids.
Indeed, it was recently suggested that consideration be given to changing the name antiphospholipid antibodiesthe term frequently used today for both lupus anticoagulant of others22.".'7,2X,,7Y In . providing strong evidence that lupus
IgG and aCL antibodies-to the name antiphospholipidprotein antibodies!' This would be appropriate for antibodies that bind to an epitope forming after p2GPI binds to anionic phospholipid and possibly for other antibodies in lupus anticoagulant plasmas.39 However, with the data presented here, substantial evidence now exists that lupus anticoagulant plasmas may contain antibodies that can bind to prothrombin independent of an initial calcium-mediated reaction between prothrombin and anionic phospholipid. This evidence may be summarized as follows.
(1) The demonstration in crossed immunoelectrophoresis experiments by others" and later in this laboratory*' of the presence of prothrombidprothrombin antibody complexes in the plasma of most patients with a lupus anticoagulant. (2) The present finding of increased amounts of prothrombin in IgG prepared by protein A chromatography of lupus anticoagulant plasmas over the neglibile amounts of prothrombin in IgG prepared by protein A chromatography of normal plasmas. (3) The present demonstration that IgG prepared from lupus anticoagulant plasmas by protein A chromatography can bind to prothrombin on Western blots in the absence of phospholipid and calcium ions. This is in contrast to the inability of the IgG to bind to P2GPI on Western blots under similar conditions. (4) The earlier initial data from this laboratory" and the more substantial quantitative data presented here that IgG with lupus anticoagulant activity can be adsorbed from citrated lupus anticoagulant plasmas in the absence of any added calcium and phospholipid by prothrombin affinity chromatography and recovered in the IgG of eluates from the prothrombin column. The above evidence that IgG in lupus anticoagulant plasmas can bind directly to prothrombin may be viewed as indirect support for the hypothesis that lupus anticoagulant IgG, after its binding to prothrombin, binds to anionic phospholipid as a "passenger" after the calcium-ion mediated binding of prothrombin to anionic phospholipid. However, additional experiments to test this hypothesis are needed and are underway in this laboratory.
Whatever the binding mechanism, the data obtained from our experiments with prothrombin affinity chromatography of lupus anticoagulant plasmas provide clear evidence that IgG with specificity towards prothrombin can inhibit the coagulant function of anionic phospholipid in in vitro assay systems. Although, for the reasons discussed, we could not obtain unequivocal functional data with IgG separated by protein A chromatography, our functional and binding data, taken as a whole, lead us to believe that the presence of prothrombin is obligatory for the expression of anticoagulant activity by many, if not a substantial majority, of lupus anticoagulant plasmas.
In an occasional patient, antiprothrombin antibodies are present in high enough titer to deplete the blood of prothrombin as a consequence of the accelerated clearance of prothrombidantiprothrombin complexes with the resultant potential for serious clinical bleeding.''.'' Whether antiprothrombin antibodies-through binding as prothrombidantiprothrombin complexes to phospholipid in the phospholipiddependent coagulation reactions of hemostasis-contribute to the increased risk for thrombosis of patients with a lupus anticoagulant is an important question in need of an answer.
